Trial reportPloS one2012
MiR-128 inhibits tumor growth and angiogenesis by targeting p70S6K1.
Trial report in PloS one, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 87 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
87 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- A comprehensive meta-analysis of circulation miRNAs in glioma as potential diagnostic biomarker.PloS one · 2018Pooled it
- A systematic review of microRNA in glioblastoma multiforme: micro-modulators in the mesenchymal mode of migration and invasion.Molecular neurobiology · 2013Pooled it
- Non-coding RNAs-based Therapy and Angiogenesis: A New Era for the Management of Gliomas.Current gene therapy · 2026Review
- Engineered smart materials for RNA based molecular therapy to treat Glioblastoma.Bioactive materials · 2024Article
- Glioblastoma Therapy: Past, Present and Future.International journal of molecular sciences · 2024Review
- MicroRNA biomarkers as next-generation diagnostic tools for neurodegenerative diseases: a comprehensive review.Frontiers in molecular neuroscience · 2024Review
- miR-221-3p targets Ang-2 to inhibit the transformation of HCMECs to tip cells.Journal of cellular and molecular medicine · 2023Article
- Dissecting the Methylomes ofCancers · 2023Article
- ADAMTS9-AS1 Long Non‑coding RNA Sponges miR‑128 and miR-150 to Regulate Ras/MAPK Signaling Pathway in Glioma.Cellular and molecular neurobiology · 2023Article
- microRNAs (miRNAs) in Glioblastoma Multiforme (GBM)-Recent Literature Review.International journal of molecular sciences · 2023Review
- LINC02381-ceRNA exerts its oncogenic effect through regulation of IGF1R signaling pathway in glioma.Journal of neuro-oncology · 2022Article
- Deciphering of Adult Glioma Vulnerabilities through Expression Pattern Analysis of GABA, Glutamate and Calcium Neurotransmitter Genes.Journal of personalized medicine · 2022Article
- The role of miR-128 in cancer development, prevention, drug resistance, and immunotherapy.Frontiers in oncology · 2022Review
- MicroRNA-128b mediates lipopolysaccharide-induced apoptosis via reactive oxygen species in human pulmonary microvascular endothelial cells.Clinics (Sao Paulo, Brazil) · 2022Article
- Role of microRNAs in glioblastoma.Oncotarget · 2021Article
- TFEB Signalling-Related MicroRNAs and Autophagy.Biomolecules · 2021Review
- miRNA-128 modulates bone neoplasms cells proliferation and migration through the WNT/β-catenin and EMT signal pathways.Journal of orthopaedic surgery and research · 2021Article
- MicroRNA as an Important Target for Anticancer Drug Development.Frontiers in pharmacology · 2021Review
- Non-Coding RNAs in Glioma Microenvironment and Angiogenesis.Frontiers in molecular neuroscience · 2021Review
- The Emerging Field of Noncoding RNAs and Their Importance in Pediatric Diseases.The Journal of pediatrics · 2020Article
27 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
MicroRNAs are a class of small noncoding RNAs that function as critical gene regulators through targeting mRNAs for translational repression or degradation. In this study, we showed that miR-128 expression levels were decreased in glioma, and identified p70S6K1 as a novel direct target of miR-128. Overexpression of miR-128 suppressed p70S6K1 and its downstream signaling molecules such as HIF-1 and VEGF expression, and attenuated cell proliferation, tumor growth and angiogenesis. Forced expression of p70S6K1 can partly rescue the inhibitory effect of miR-128 in the cells. Taken together, these findings will shed light to the role and mechanism of miR-128 in regulating glioma tumor angiogenesis via miR-128/p70S6K1 axis, and miR-128 may serve as a potential therapeutic target in glioma in the future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.